157 related articles for article (PubMed ID: 34269012)
1. Pharmacokinetic interactions between the potential COVID-19 treatment drugs lopinavir/ritonavir and arbidol in rats.
Hu Y; Zuo M; Wang X; Wang R; Li L; Lu X; Jiang S
J Zhejiang Univ Sci B; 2021 Jul; 22(7):599-602. PubMed ID: 34269012
[TBL] [Abstract][Full Text] [Related]
2. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study.
Deng L; Li C; Zeng Q; Liu X; Li X; Zhang H; Hong Z; Xia J
J Infect; 2020 Jul; 81(1):e1-e5. PubMed ID: 32171872
[TBL] [Abstract][Full Text] [Related]
3. Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19.
Xie X; Jiang Y; Zeng Y; Liu H
Antivir Ther; 2020; 25(4):233-239. PubMed ID: 32496210
[TBL] [Abstract][Full Text] [Related]
4. Safety of protease inhibitors and Arbidol for SARS-CoV-2 pneumonia in Zhejiang Province, China.
Guo YZ; Xu KJ; Li YT; Fu JD; Xu M; Yu L; Sheng JF; Zhu B
J Zhejiang Univ Sci B; 2020 Dec.; 21(12):948-954. PubMed ID: 33843160
[TBL] [Abstract][Full Text] [Related]
5. [The efficacy and safety of lopinavir/ritonavir and arbidol in patients with coronavirus disease 2019].
Wen CY; Xie ZW; Li YP; Deng XL; Chen XT; Cao Y; Ou X; Lin WY; Li F; Cai WP; Li LH
Zhonghua Nei Ke Za Zhi; 2020 Aug; 59(8):605-609. PubMed ID: 32388937
[No Abstract] [Full Text] [Related]
6. Comparative effectiveness of Lopinavir/Ritonavir-based regimens in COVID-19.
Qu J; Li GH; Wang JJ; He GF; Huang JJ; Chen Y; Qu Q; Chen XY; Lu Q
Clin Exp Pharmacol Physiol; 2021 Feb; 48(2):203-210. PubMed ID: 33090501
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial.
Li Y; Xie Z; Lin W; Cai W; Wen C; Guan Y; Mo X; Wang J; Wang Y; Peng P; Chen X; Hong W; Xiao G; Liu J; Zhang L; Hu F; Li F; Zhang F; Deng X; Li L
Med; 2020 Dec; 1(1):105-113.e4. PubMed ID: 32838353
[TBL] [Abstract][Full Text] [Related]
8. Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment.
Magro P; Zanella I; Pescarolo M; Castelli F; Quiros-Roldan E
Biomed J; 2021 Mar; 44(1):43-53. PubMed ID: 33608241
[TBL] [Abstract][Full Text] [Related]
9. Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19.
Kocayiğit H; Özmen Süner K; Tomak Y; Demir G; Yaylacı S; Dheir H; Güçlü E; Erdem AF
J Clin Pharm Ther; 2021 Apr; 46(2):454-459. PubMed ID: 33128482
[TBL] [Abstract][Full Text] [Related]
10. Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study.
Choi MJ; Kang M; Shin SY; Noh JY; Cheong HJ; Kim WJ; Jung J; Song JY
Int J Infect Dis; 2021 Jan; 102():275-281. PubMed ID: 33127507
[TBL] [Abstract][Full Text] [Related]
11. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
Uzunova K; Filipova E; Pavlova V; Vekov T
Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of arbidol versus lopinavir/ritonavir in the treatment of coronavirus disease 2019.
Yu M; Wang DC; Li S; Lei YH; Wei J; Huang LY
J Med Virol; 2022 Apr; 94(4):1513-1522. PubMed ID: 34837230
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
Costanzo M; De Giglio MAR; Roviello GN
Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection.
Smolders EJ; Te Brake LH; Burger DM
Antivir Ther; 2020; 25(7):345-347. PubMed ID: 32589165
[TBL] [Abstract][Full Text] [Related]
15. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19.
Zhu Z; Lu Z; Xu T; Chen C; Yang G; Zha T; Lu J; Xue Y
J Infect; 2020 Jul; 81(1):e21-e23. PubMed ID: 32283143
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of methylprednisolone and the combined use of lopinavir/ritonavir with arbidol in treatment of coronavirus disease 2019.
Xia Q; Dai W; Xu K; Ni Q; Li Y; Liu J; Zhao H; Guo Y; Yu L; Yi P; Su J; Lang G; Tao J; Shi D; Wu W; Wu X; Xu Y; Xu M; Yu L; Wang X; Cai H; Fang Q; Zhou J; Qiu Y; Li L
J Med Virol; 2021 Jul; 93(7):4446-4453. PubMed ID: 33448426
[TBL] [Abstract][Full Text] [Related]
17. Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: A pilot retrospective study.
Lan X; Shao C; Zeng X; Wu Z; Xu Y
Int J Clin Pharmacol Ther; 2021 May; 59(5):378-385. PubMed ID: 33624583
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
19. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study.
Liu X; Chen H; Shang Y; Zhu H; Chen G; Chen Y; Liu S; Zhou Y; Huang M; Hong Z; Xia J
Trials; 2020 Jul; 21(1):622. PubMed ID: 32641091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
